Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.60 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | CNR1 | P21554 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | CNR2 | P34972 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2154639 | 0.92 | ALDH1A1 (0.56) | NPC1ALDH1A1SMN1; SMN2 | |
| SCHEMBL28729042 | 0.85 | CNR2 (0.49) | NPC1RAB9ACNR1ALDH1A1CNR2 | |
| SCHEMBL5670080 | 0.84 | KDM4E (0.52) | NPC1ALDH1A1 | |
| SCHEMBL5670087 | 0.84 | KDM4E (0.52) | NPC1ALDH1A1 | |
| SCHEMBL12799245 | 0.84 | KDM4E (0.52) | NPC1ALDH1A1 | |
| SCHEMBL13593327 | 0.83 | NPC1 (0.43) | NPC1EPHX1KMT2AALDH1A1 | |
| SCHEMBL31661778 | 0.82 | ALDH1A1 (0.50) | NPC1ALDH1A1SMN1; SMN2 | |
| SCHEMBL6175361 | 0.82 | NPC1 (0.61) | NPC1EPHX1RAB9AP2RX7KMT2A | |
| SCHEMBL19747534 | 0.82 | NPC1 (0.60) | NPC1EPHX1RAB9AP2RX7KMT2A | |
| SCHEMBL12798265 | 0.81 | ALDH1A1 (0.48) | NPC1CNR1ALDH1A1SMN1; SMN2CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119661459-A | 1,2, 3-Benzotriazine-4 (3H) -one seleno compound and preparation method and application thereof | 赣南师范大学 | 2025-03-21 | — | — | CN | claimed |
| CN-119661459-A | 1,2, 3-Benzotriazine-4 (3H) -one seleno compound and preparation method and application thereof | 赣南师范大学 | 2025-03-21 | — | — | CN | disclosed |
| US-20070238763-A1 | Urea derivatives as integrin a4 antagonists | LABORATORIOS ALMIRALL, S.A. | 2007-10-11 | — | — | US | disclosed |
| EP-1383750-B1 | UREA DERIVATIVES AS INTEGRIN ALPHA 4 ANTAGONISTS | ALMIRALL LAB (ES) | 2007-09-26 | — | — | EP | disclosed |
| US-7253171-B2 | Urea derivatives as integrin α4 antagonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2007-08-07 | — | — | US | disclosed |
| US-20040142982-A1 | Urea derivatives as integrin alpha 4 antagonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2004-07-22 | — | — | US | disclosed |
| EP-1383750-A2 | UREA DERIVATIVES AS INTEGRIN ALPHA 4 ANTAGONISTS | Almirall Prodesfarma, S.A. (ES) | 2004-01-28 | — | — | EP | disclosed |
| WO-2002057242-A2 | UREA DERIVATIVES AS INTEGRIN ALPHA 4 ANTAGONISTS | ALMIRALL PRODESFARMA, S.A. (ES) | 2002-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142982-A1 | Urea derivatives as integrin alpha 4 antagonists | ITGA4, ITGB4, ITGA1 | NPC1 3712/4885EPHX1 3623/4885RAB9A 1450/4885 |
| US-20070238763-A1 | Urea derivatives as integrin a4 antagonists | ITGB4, ITGA4, ITGB7 | NPC1 3643/4885EPHX1 1926/4885RAB9A 2031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.